DMSO and colchicine therapy in amyloid disease.
There is no specific therapy for primary amyloidosis, and acquired generalised amyloidosis can be treated only if the underlying disease is eliminated. In this study we have investigated the role of colchicine therapy in primary amyloidosis, and dimethylsulphoxide (DMSO) in leprosy associated secondary amyloidosis. No effect on creatinine clearance or 24 h proteinuria could be observed in the patients with primary amyloidosis. In the DMSO group renal function was considerably improved in 3 patients with moderate renal failure but not in those with severe renal impairment (creatinine clearance less than 10 ml/min). Serum SAA determinations were not particularly informative. These findings point to a beneficial effect of DMSO in human secondary amyloidosis when given at an early stage of renal involvement.
D000686:Amyloidosis / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D003078:Colchicine / Q000627:therapeutic use*; D004121:Dimethyl Sulfoxide / Q000627:therapeutic use*; D006801:Humans; D007674:Kidney Diseases / Q000188:drug therapy / Q000209:etiology; D007677:Kidney Function Tests; D007918:Leprosy / Q000150:complications; D000685:Serum Amyloid A Protein / Q000032:analysis
D000685:Serum Amyloid A Protein; D003078:Colchicine; D004121:Dimethyl Sulfoxide